Save on Secukinumab with Coupons, Discounts & Savings Programs

Secukinumab is available in the following:

• Subcutaneous Injection
  300 mg/2 mL solution in a single-dose UnoReady® pen and in a single-dose prefilled syringe
  150 mg/mL solution in a single-dose Sensoready® pen and in a single-dose prefilled syringe
  75 mg/0.5 mL solution in a single-dose prefilled syringe (for pediatric patients) Intravenous Infusion
• 125 mg/5 mL solution in a single-dose vial

Secukinumab is an interleukin 17 (IL-17) inhibitor and is used for the following:

• Plaque psoriasis (PsO) in people ages 6 years and older
• Psoriatic arthritis (PsA) in people ages 2 years and older who weigh at least 33 lbs
• Ankylosing spondylitis (AS) in adults
• Non-radiographic axial spondyloarthritis (nr-axSpA) in adults
• Enthesitis-related arthritis in people ages 4 years and older who weigh at least 33 lbs
• Hidradenitis suppurativa in adults

Secukinumab is a monoclonal antibody that works as an interleukin inhibitor. It blocks a protein in your immune system called interleukin-17 (IL-17), which tends to be overly active in certain inflammatory conditions. In doing so, Secukinumab lowers swelling, pain, and inflammation.

Secukinumab is dosed as follows:

Adults

• Plaque psoriasis (PsO) and hidradenitis suppurativa: The typical starting dose is 300 mg injected under the skin weekly for 5 weeks. After that, the maintenance dose is usually 300 mg injected monthly
• Psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA): The starting dose can be optional; if given, the typical dose is 150 mg injected under the skin (SQ) weekly for 5 weeks. After that, the maintenance dose is usually 150 mg injected under the skin monthly. If appropriate, your provider might raise your dose to 300 mg monthly

Children

• Secukinumab is approved for children to treat PsO (ages 6 years and older), PsA (ages 2 years and older), and enthesitis-related arthritis (ages 4 years and older)
• Body weight 33 lbs to 110 lbs: The typical starting dose is 75 mg injected under the skin weekly for 5 weeks. After that, the maintenance dose is usually 75 mg injected monthly
• Body weight 110 lbs or more: The typical starting dose is 150 mg injected under the skin weekly for 5 weeks. After that, the maintenance dose is usually 150 mg injected monthly
• Secukinumab can also be given as an injection through the veins for PsA, AS, and nr-axSpA for adults only. Your provider will calculate the dose based on your body weight. The injection is usually given by a healthcare provider in a clinic setting

Secukinumab is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Secukinumab:

• Diarrhea
• Upper respiratory infections
• Common cold

Serious side effects are rare with Secukinumab. Contact your healthcare provider immediately if you experience any of the following.

• Serious allergic reactions: difficulty breathing; hives; swelling of your face, lips, tongue, or throat
• Infection: fever; cough; difficulty breathing; diarrhea; weakness; sweating; chills; scaly, itchy, or burning skin

The following medications may interact with Secukinumab:

• Upon beginning or stopping Secukinumab in patients who are receiving concomitant CYP450 substrates
• particularly those where minimal decreases in the concentration may reduce CYP substrate effectiveness or minimal increases in the concentration may increase CYP substrate adverse reactions, consider monitoring for therapeutic effect or concentration of the CYP substrate and consider dosage adjustment of the CYP substrate as needed

Various FDA-approved generic manufacturers

It is not known if Secukinumab can harm your unborn baby. You and your healthcare provider should decide if you will use Secukinumab.

• Cosentyx